Dec 1, 2020 12:30 pm EST Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
Nov 25, 2020 8:30 am EST Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
Aug 18, 2020 9:35 am EDT The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
Jul 21, 2020 9:35 am EDT Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
Apr 30, 2020 10:30 am EDT Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
Dec 4, 2019 9:35 am EST First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
Aug 6, 2019 9:35 am EDT The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings’ LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas
Jul 18, 2019 9:35 am EDT First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology’s LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome
Jun 25, 2019 9:35 am EDT Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
May 15, 2019 9:35 am EDT Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors
